tradingkey.logo
tradingkey.logo
Search

MANE.NB

MANE
Add to Watchlist
100.910USD
-1.970-1.91%
Close 05/29, 16:00ETQuotes delayed by 15 min
4.22BMarket Cap
6.27P/E TTM

More Details of MANE.NB Company

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

MANE.NB Info

Ticker SymbolMANE
Company nameVeradermics Inc
IPO dateFeb 04, 2026
CEOWaldman (Reid Alexander)
Number of employees19
Security typeOrdinary Share
Fiscal year-endFeb 04
Address- -
City- -
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolMANE
IPO dateFeb 04, 2026
CEOWaldman (Reid Alexander)

Company Executives of MANE.NB

Name
Name/Position
Position
Shareholding
Change
Dr. Timothy (Tim) Durso, M.D.
Dr. Timothy (Tim) Durso, M.D.
President, Co-Founder
President, Co-Founder
234.91K
-0.63%
,
,
--
--
Dr. Reid Waldman, M.D.
Dr. Reid Waldman, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. Jane M. Grant-Kels, M.D.
Dr. Jane M. Grant-Kels, M.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Independent Director
Independent Director
--
--
Mr. Dominic Carrano, CPA
Mr. Dominic Carrano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mark Neumann
Mr. Mark Neumann
Chief Commercial and Strategy Officer
Chief Commercial and Strategy Officer
--
--
Mr. Michael V. Greco, J.D.
Mr. Michael V. Greco, J.D.
General Counsel
General Counsel
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Timothy (Tim) Durso, M.D.
Dr. Timothy (Tim) Durso, M.D.
President, Co-Founder
President, Co-Founder
234.91K
-0.63%
,
,
--
--
Dr. Reid Waldman, M.D.
Dr. Reid Waldman, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. Jane M. Grant-Kels, M.D.
Dr. Jane M. Grant-Kels, M.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Tue, May 12
Updated: Tue, May 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Longitude Capital Management Co., LLC
11.14%
Suvretta Capital Management, LLC
9.98%
SR One Capital Management, LP
5.75%
Prospect Hill Growth Partners, L.P.
5.27%
Viking Global Investors LP
5.15%
Other
62.71%
Shareholders
Shareholders
Proportion
Longitude Capital Management Co., LLC
11.14%
Suvretta Capital Management, LLC
9.98%
SR One Capital Management, LP
5.75%
Prospect Hill Growth Partners, L.P.
5.27%
Viking Global Investors LP
5.15%
Other
62.71%
Shareholder Types
Shareholders
Proportion
Venture Capital
17.13%
Hedge Fund
13.70%
Investment Advisor
9.96%
Investment Advisor/Hedge Fund
9.08%
Private Equity
5.35%
Individual Investor
2.78%
Other
42.00%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
32
22.69M
57.31%
+18.80M

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Longitude Capital Management Co., LLC
4.65M
12.46%
+4.65M
--
Feb 05, 2026
Suvretta Capital Management, LLC
4.17M
11.16%
+4.17M
--
Feb 06, 2026
SR One Capital Management, LP
2.40M
6.43%
+2.40M
--
Feb 05, 2026
Prospect Hill Growth Partners, L.P.
1.91M
5.11%
+1.91M
--
Feb 04, 2026
Viking Global Investors LP
2.15M
5.76%
+2.15M
--
Feb 05, 2026
Citadel Advisors LLC
1.40M
3.75%
+1.40M
--
Feb 04, 2026
JP Morgan Asset Management
56.58K
0.15%
+56.58K
--
Feb 28, 2026
The Vanguard Group, Inc.
48.29K
0.13%
+48.29K
--
Feb 28, 2026
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI